New cancer-fighting nanodrug tops Houston innovation news to know

Trending News

The team developed Nano-273, which helps the immune system fight pancreatic and lung cancers. Photo courtesy UH

Editor's note: The new year brings big Houston innovation news, from pending retirements to new hires and a cancer-fighting nanodrug. Below are the five most-read InnovationMap stories published January 16-30, 2026:

1. Houston team uses CPRIT funding to develop nanodrug for cancer immunotherapy

Wei Gao (center), a UH assistant professor of pharmacology, and her team have developed Nano-273, which helps the immune system fight pancreatic and lung cancers. Photo courtesy UH.

With a relative five-year survival rate of 50 percent, pancreatic cancer is a diagnosis nobody wants. At 60 percent, the prognosis for lung cancer isn’t much rosier. That’s because both cancers contain regulatory B cells (Bregs), which block the body’s natural immunity, making it harder to fight the enemies within. Newly popular immunotherapies in a category known as STING agonists may stimulate natural cancer defenses. However, they can also increase Bregs while simultaneously causing significant side effects. But Wei Gao, assistant professor of pharmacology at the University of Houston College of Pharmacy, may have a solution to that conundrum. Continue reading.

2. Rice Alliance and the Ion leader Brad Burke to retire this summer

Houston entrepreneurship and innovation leader Brad Burke is set to retire on June 30. Photo by Jeff Fitlow/Rice University

Brad Burke—a Rice University associate vice president who leads the Ion District’s Rice Alliance for Technology and Entrepreneurship and is a prominent figure in Houston’s startup community—is retiring this summer after a 25-year career at the university. Burke will remain at the Rice Alliance as an adviser until his retirement on June 30. Continue reading.

3. 5+ must-know application deadlines for Houston innovators

The University of Michigan's Intero Biosystems earned a top-place finish and the largest total investment from the 2025 Rice Business Plan Competition. Photo courtesy Rice University.

As 2026 ramps up, the Houston innovation scene is looking for the latest groups of innovative startups that'll make an impact. A number of accelerators and competitions have opened applications. See which might be a good fit for you or your venture, and take careful note of the deadlines. Continue reading.

4. Houston startups closed $1.75 billion in 2025 VC funding, says report

Local startups collected $1.75 billion in venture capital in 2025. Photo via Pexels.

Going against national trends, Houston-area startups raised 7 percent less venture capital last year than they did in 2024, according to the PitchBook-NVCA Venture Monitor report. The report shows local startups collected $1.75 billion in venture capital in 2025, down from $1.89 billion the previous year. Continue reading.

5. Baylor College of Medicine names Minnesota med school dean as new president, CEO ​

Baylor College of Medicine has named Dr. Jakub Tolar as its new president, CEO and executive dean. Photo courtesy of Mendel Lectures.

Dr. Jakub Tolar, dean of the University of Minnesota Medical School, is taking over as president, CEO and executive dean of Houston’s Baylor College of Medicine on July 1. Tolar—who’s also vice president for clinical affairs at the University of Minnesota and a university professor—will succeed Dr. Paul Klotman as head of BCM. Klotman is retiring June 30 after leading Texas’ top-ranked medical school since 2010. Continue reading.

At Rezvani Lab in MD Anderson Cancer Center, scientists train immune cells to fight cancer. Photo via Getty Images

Unique cell therapy developed in Houston doses inaugural patient

cancer-fighting innovation

Replay, a genome-writing company headquartered in San Diego, has announced that its first patient has been dosed with an engineered T-Cell Receptor Natural Killer (TCR-NK) cell therapy for relapsed or refractory multiple myeloma.

What does that have to do with Houston? Last year, Replay incorporated a first-in-class engineered TCR-NK cell therapy product company, Syena, using technology developed by Dr. Katy Rezvani at The University of Texas MD Anderson Cancer Center.

Rezvani, a professor of stem cell transplantation and cellular therapy, is the force behind MD Anderson’s Rezvani Lab, a group of 55 people, all focused on harnessing natural killer cells to combat cancer.

“Everybody thinks that the immune system is fighting viruses and infections, but I feel our immune system is capable of recognizing and killing abnormal cells or cells that are becoming cancerous and they're very powerful. This whole field of immunotherapy really refers to the power of the immune system,” Rezvani tells InnovationMap.

Dr. Katy Rezvani is a professor of stem cell transplantation and cellular therapy and the force behind MD Anderson’s Rezvani Lab, which is focused on harnessing natural killer cells to combat cancer. Photo via mdanderson.org

At Rezvani Lab, scientists train immune cells to fight cancer. While cancer drugs like chemotherapy are still the norm, immunotherapy has gained ground, led by Houston research, including the work of Nobel laureate Jim Allison. The harnessed cells are taught to attack cancerous cells, while ignoring healthy ones, says Rezvani. “We’re turning them into heat-seeking missiles,” she explains.

However, there must be a beacon to signal to those “missiles” that there is something to attack. Much of the field has used chimeric antigen receptors (CARs) to achieve that. But they have limitations.

“CARs can only recognize beacons that sit on the surface of the tumor cells,” Rezvani says. “So basically, it's like the tumor cell has to have a hat on it.”

She says that this usually means that the targets that send off a signal are relatively limited, mostly blood cancers. Using T cell receptors (TCRs) may be able to open up the field to look beyond the “hat.” In other words, TCRs can peer inside cells and see what differentiates a tumor cell from healthy cells. With Replay, Rezvani Lab has developed a first-in-class and first-in-human approach of engineering natural killer cells to express the TCR.

There are six different FDA-approved products that use CAR-T cells, but Rezvani says that her TCR-NK-based technology, though still in its early phases, shows great promise.

“We could use it to target many different types of antigens, many different types of cancers, especially solid tumors," she explains. "These cell therapies have a lot of potential — we call them living drugs… It's not like chemotherapy where you have to keep giving different multiple cycles, these cells are very long lived.”

Rezvani, who started her career in London, says that Houston has been instrumental in the success of her lab.

“There are so many opportunities because we have access to some of the most brilliant minds in research,” Rezvani says. “We have some of the best clinicians in the world. We have patients who come to us who are willing to participate in our clinical trials — really put their trust in us — and are committed and want to participate in these clinical studies.”

The role of funding also plays a part. As Rezvani admitted, bringing a new technology to the market is expensive. The philanthropists who help support trials can’t be forgotten among Houston’s finest.

Whether or not Syena produces the first TCR-NK product on the market, Rezvani is enthusiastic and hopeful for the future of her patients.

“The field of immunotherapy is really expanding, the field of cell therapies is expanding, and there is so much promise,” she says. “The promise of AI, big data, all the engineering tools that we have available, the promise of CRISPR — all of that is going to bring what we've learned from biology, from basic science, together to help us make the cell therapies that are going to be safe and and also very effective for our patients.”

A Houston health care company received the green light from the FDA to advance a treatment that's targeting a deadly cancer. Photo via Getty Images

Houston immunotherapy company achieves FDA designation for cancer-fighting vaccine

got the green light

The FDA has granted a Houston-based company a Fast Track designation.

Diakonos Oncology Corp. is a clinical-stage immuno-oncology company that has developed a unique dendritic cell vaccine, DOC1021. The vaccine targets glioblastoma multiforme (GBM), the most common and most lethal malignant brain tumor in adults. The aggressive tumors come with a life expectancy of about 15 months following diagnosis. About 7 percent of those diagnosed survive five years, while the 10-year outlook only sees a one-percent survival rate.

“The FDA’s decision acknowledges the potential of this new treatment approach for a very challenging disease,” Diakonos CEO Mike Wicks says in a press release. “Our protocol represents a first for cancer immunotherapy and could be viable for many types of cancers beyond GBM.”

FDA Fast Track designations are intended to expedite the haste with which drugs with early clinical promise are reviewed, likely taking them to market faster.

DOC1021 uses the body’s natural anti-viral immune response to fight GBM. The vaccine mimics viral infection with the patient’s cancer markers. Essentially, DOC1021 uses the body’s own natural ability to detect and eliminate infected cells.

The technology uses dendritic cells, white blood cells that are able to perceive threats, to its advantage. The unique cancer markers are loaded both internally and externally into the immune cells, just as they would simultaneously occur in a viral infection. The individualized treatment is administered through three precise injections that target deep cervical lymph node chains. By dosing this way, the immune responses are directed straight to the central nervous system.

The results have spoken for themselves: All of the patients who have tried the treatment have exceeded survival expectations. And just as importantly, DOC1021 appears to be extremely safe. No serious adverse effects have been reported.

“Because Phase I clinical trials are generally not statistically powered to demonstrate efficacy, detection of a statistically significant efficacy signal is very promising,” says William Decker, associate professor of immunology at Baylor College of Medicine and inventor of the DOC1021 technology.

The Phase 1 open-label trial of DOC1021 (NCT04552886) is currently taking place at both the University of Texas Health Science Center in Houston and at the MD Anderson Cancer Center at Cooper University Health Care in Camden, NJ. The trial is expected to complete this year.

7 Hills Pharma, an innovative immunotherapy company, was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas. Photo via Getty Images

Houston immunotherapy company to use $13.5M grant to further develop cancer treatments

future of pharma

Between Bangalore and Chennai in the Indian state of Andhra Pradesh, you’ll find the town of Tirupati. It’s home to seven peaks that host a Hindu temple complex devoted to a form of Vishnu, Venkateshvara. It is also the region from which Upendra Marathi originally hails. It’s where his father, and many other family members, attended medical school.

“My father’s first job was to take care of the pilgrims,” recalls Marathi.

It's only natural that his groundbreaking Houston company would be named 7 Hills Pharma.

“That sort of selflessness and giving back, I wanted to embody it in the name of the company,” Marathi says.

Now, 7 Hills Pharma is announcing that last month, it was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). That’s on top of more than $13 million in NIH grants, making the company the second largest recipient of SBIR/STTR grants in Texas.

Launched in 2016, 7 Hills Pharma is working to develop drugs that can overcome the all-too-common problem of immunotherapy resistance. Thanks to the Nobel Prize-winning work of Jim Allison in the realm of immuno-oncology, the field was “very hot” at the time, says Marathi, particularly in Houston.

So what has 7 Hills developed? Oral small molecules that activate integrins — the receptors that allow cells to bind to one another — allowing for the cell-to-cell interactions that create a successful immune response to immune checkpoint inhibitors such as Yervoy. In other words, they have created capsules that increase the effectiveness of drugs that allow the body’s own immune response to fight cancers.

But that’s not all. Tests have shown that the same discovery, called alintegimod, can also augment the effectiveness of vaccines. The pill, which co-founder and co-inventor Peter Vanderslice calls “a beautiful way to amplify the vaccines,” can potentially be applied to anything from influenza to coronavirus.

Their greatest challenge, says Vanderslice, is the very fact that the technology is so novel.

“Most large pharmas are very risk averse,” he explains. “They only want to do ‘me-too’ kinds of drugs.”

7 Hills Pharma is the third company Marathi, both a PhD and an MBA, has helped to found based on technology he co-invented. Vanderslice is director of the molecular cardiology research laboratories at The Texas Heart Institute.

“It’s very much a homegrown company,” Marathi says.

And a small one, at least for now. Working out of JLabs@TMC, the full-time team is currently just Marathi and Siddhartha De, the senior director of development. Marathi convinced De to transplant himself and his family from India for the purpose of assisting 7 Hills with preparing its drugs for clinical readiness.

The CPRIT funds will allow 7 Hills Pharma to hire several long-time team members full-time and with benefits.

“The bringing of talent and bringing of technology to TMC and what was born at Texas Heart Institute is rather remarkable,” says Rob Bent, the company’s director of operations.

The next step for 7 Hills Pharma is a Phase Ib/IIa clinical trial in patients with treatment-resistant solid tumors. And the team just finalized the deck that will help raise another $10 million to $250 million in the company’s series A. And hopefully sooner rather than later, a new set of medical pilgrims will be thanking 7 Hill Pharma for its care.

A UH professor is fighting cancer with a newly created virus that targets the bad cells and leaves the good ones alone. Photo via Getty Images

University of Houston researchers snag $1.8M to develop cancer-fighting virus

immunotherapy innovation

Viruses attack human cells, and that's usually a bad thing — some Houston researchers have received fresh funding to develop and use the evil powers of viruses for good.

The developing cancer treatment is called oncolytic virotherapy and has risen in popularity among immunotherapy research. The viruses can kill cancer cells while being ineffective to surrounding cells and tissue. Basically, the virus targets the bad guys by "activating an antitumor immune response made of immune cells such as natural killer (NK) cells," according to a news release from the University of Houston.

However exciting this rising OV treatment seems, the early stage development is far from perfect. Shaun Zhang, director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston, is hoping his work will help improve OV treatment and make it more effective.

“We have developed a novel strategy that not only can prevent NK cells from clearing the administered oncolytic virus, but also goes one step further by guiding them to attack tumor cells. We took an entirely different approach to create this oncolytic virotherapy by deleting a region of the gene which has been shown to activate the signaling pathway that enables the virus to replicate in normal cells,” Zhang says in the release.

Zhang, who is also a M.D. Anderson professor in the Department of Biology & Biochemistry, has received a $1.8 million grant from the National Institutes of Health to continue his work.

Zhang and his team are specifically creating a new OV — called FusOn-H2 and based on the Herpes simplex 2 virus.

“Our recent studies showed that arming FusOn-H2 with a chimeric NK engager (C-NK-E) that can engage the infiltrated natural killer cells with tumor cells could significantly enhance the effectiveness of this virotherapy,” he says. “Most importantly, we observed that tumor destruction by the joint effect of the direct oncolysis and the engaged NK cells led to a measurable elicitation of neoantigen-specific antitumor immunity.”

Shaun Zhang is the director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston and M.D. Anderson professor in the Department of Biology & Biochemistry. Image via UH.edu

Houston's Nobel Prize winner, Jim Allison, is the star of Breakthrough, which premieres on Independent Lens at 9 pm Monday, April 27, on PBS, PBS.org, and the PBS Video App. Photo via SXSW.com

Documentary featuring Houston Nobel Prize winner to air on PBS

to-watch list

Not all heroes wear capes. In fact, our current coronavirus heroes are donning face masks as they save lives. One local health care hero has a different disease as his enemy, and you'll soon be able to stream his story.

Dr. James "Jim" Allison won the 2018 Nobel Prize in Physiology or Medicine for his work in battling cancer by treating the immune system — rather than the tumor. Allison, who is the chair of Immunology and executive director of the Immunotherapy Platform at MD Anderson Cancer Center, has quietly and often, singularly, waged war with cancer utilizing this unique approach.

The soft-spoken trailblazer is the subject of an award-winning documentary, Jim Allison: Breakthrough, which will air on PBS and its streaming channels on Monday, April 27 at 9 pm (check local listings for channel information). Lauded as "the most cheering film of the year" by the Washington Post, the film follows Allison's personal journey to defeat cancer, inspired and driven by the disease killed his mother.

Breakthrough is narrated by Woody Harrelson and features music by Willie Nelson, adding a distinct hint of Texana. (The film was a star at 2019's South by Southwest film festival.) The documentary charts Alice, Texas native as he enrolls at the University of Texas, Austin and ultimately, cultivates an interest in T cells and the immune system — and begins to frequent Austin's legendary music scene. Fascinated by the immune system's power to protect the body from disease, Allison's research soon focuses on how it can be used to treat cancer.

Viewers will find Allison charming, humble, and entertaining: the venerable doctor is also an accomplished blues harmonica player. Director Bill Haney weaves Allison's personal story with the medical case of Sharon Belvin, a patient diagnosed with melanoma in 2004 who soon enrolled in Allison's clinical trials. Belvin has since been entirely cancer-free, according to press materials.

"We are facing a global health challenge that knows no boundaries or race or religion, and we are all relying on gifted and passionate scientists and healthcare workers to contain and ultimately beat this thing," said Haney, in a statement. "Jim Allison and the unrelenting scientists like him are my heroes – and I'll bet they become yours!"

Jim Allison: Breakthrough premieres on Independent Lens at 9 pm Monday, April 27, on PBS, PBS.org, and the PBS Video App.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston named the No.1 emerging city for biopharma in inaugural report

Biopharma Leader

Houston is ranked No.1 on the first-ever Next 10 U.S. Biopharma Clusters report published by Genetic Engineering & Biotechnology News (GEN).

The report, which ranks the best emerging hubs for life science activities, considered patents, NIH funding, lab space, venture capital investments, and the number of jobs in regions in cities, states and “clusters” across the U.S. GEN touts Houston as the top city for the biopharma industry due to a surge in funding, job creation, medical innovations and startup success.

Here’s how Houston ranked in the report’s different categories;

  • No. 1 for NIH funding with 2,262 awards totaling more than $1.25 billion
  • No. 2 for emerging regions for jobs, with 28,000 jobs
  • No. 2 for lab space, with roughly 8 million square feet in the market
  • No. 6 for patents, with 2,760 patent families

According to BioHouston chairman Jeff Wade, Houston secured half a billion dollars in venture capital funding in 2025 and 2026 to date.

The report called out major biopharm news out of Houston in the last few months, including Bristol Myers Squibb selecting Houston for its $1 billion, 600,000-square-foot manufacturing site and Eli Lily selecting Houston for its $6.5 billion, 236-acre manufacturing site. Both facilities will be located within Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston.

Houston startups like CrossBridge Bio and Duracyte were also mentioned in the report. CrossBridge, which develops antibody-drug conjugates for cancer, was acquired by Eli Lily in April for $300 million. Duracyte, a “living pharmacy” company, was launched out of Rice University’s biotech venture studio RBL LLC this spring and is backed by up to a $45 million Advanced Research Projects Agency for Health (ARPA-H) award.

The startup is working to commercialize its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR) technology, a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time.

“There’s a lot of great talent, but the unique advantage that we have is we are able to benefit from a lot of unique clinical infrastructure and clinician insights,” Omid Veiseh, Duracyte co-founder and managing partner of RBL LLC, told GEN. “There are a lot of clinicians here who are eager to partner on investigator-initiated trials.”

The report also touted Houston’s Texas Medical Center, home to the University of Texas MD Anderson Cancer Center and Baylor College of Medicine, and international partnerships like the recently expanded TMC Korea BioBridge.

Other cities to make the list include:

  • No. 2 Minneapolis-St. Paul
  • No. 3 Denver-Boulder
  • No. 4 St. Louis
  • No. 5 Dallas-Fort Worth

States to make the list include:

  • No. 1 Ohio (including Cincinnati, Cleveland, and Columbus)
  • No. 2 Indiana (including Indianapolis)
  • No. 3 Florida (including Jacksonville and Miami-Fort Lauderdale)
  • No. 4 Georgia (including Atlanta and Augusta)
  • No. 5 Wisconsin (including Madison and Kenosha)

Regional state clusters to watch include:

  • Phoenix
  • Pittsburgh
  • Greater Richmond, Virginia
  • South Carolina
  • Utah

See the full report here.

Major Texas-based airlines ground humanoid robots as passengers

In The Air

Two major airlines based in Texas are drawing a hard line between human and humanoid: American Airlines and Southwest Airlines won’t permit human-like or animal-like robots to board flights as passengers.

Fort Worth-based American and Dallas-based Southwest recently adopted bans on robotic passengers after two incidents in which human-like robots joined flesh-and-blood passengers on Southwest flights.

In May, Aaron Mehdizadeh, owner of The Robot Studio rental company in Dallas, was heading from Las Vegas to Dallas Love Field with 3.5-foot-tall Stewie, according to CBS News Texas. Rather than shipping Stewie as cargo, Mehdizadeh bought the robot its own seat using a type of ticket often purchased for fragile items such as wedding dresses and equipment.

But because Stewie was technically a carry-on item, the robot wasn’t supposed to occupy a seat, according to eWeek. Crew members wound up disconnecting Stewie’s battery and relocating the robot to a window seat before takeoff.

Mehdizadeh pushed back on Southwest’s stance regarding the battery, telling CBS News Texas that Stewie’s power supply is a standard battery that’s similar to one for a laptop.

Stewie isn’t the only robot making mischief in the skies. In May, a 70-pound, human-like robot named Bebop caused a stir on a Southwest flight from Oakland, California, to San Diego.

The robot prompted a nearly one-hour flight delay after crew members realized it violated restrictions on large carry-ons and raised concerns about the battery, San Francisco TV station KGO reported. Dallas-based Elite Event Robotics owns Bebop.

Southwest seized Bebop’s lithium-ion battery, but the airline did let Bebop take the San Diego-bound flight.

Southwest’s new robot policy prohibits human-like or animal-like robots from riding in an airplane cabin or as checked baggage, no matter their size or purpose. All other robots, including toys, must fit in a carry-on size bag and comply with battery restrictions, the airline says.

In a statement sent to CultureMap, a Southwest spokeswoman says the airline “has taken a strong stance on this issue and has led the U.S. airline industry with our battery policy.”

“The robot policy is a further evolution of a [safety] journey we have been on for several months. This move was not in response to any single incident,” the spokeswoman adds. “To eliminate confusion, the policy applies to all similar devices, regardless of size.”

Lithium-ion batteries can overheat, catch on fire, or explode on airplanes.

American’s new robot policy, which took effect Monday, August 17, is similar to Southwest’s. The policy prohibits human-like and animal-like robots from sitting in a purchased seat, being stored in an overhead bin or traveling as checked baggage. The ban applies to U.S., international, and regional flights.

“While there have been no known events involving this type of robot on any American flight, this policy was developed following a comprehensive review of safety risks associated with these devices, including the large lithium-ion batteries that power them,” the airline said in an internal memo obtained by the View From the Wing travel blog.

American gate agents have been told not to allow a passenger accompanied by a robot to board a plane or to let a robot travel as a checked item, the memo say.

If a robot is discovered after check-in, American employees are supposed to follow the Federal Aviation Administration’s “undeclared dangerous goods” procedures. These procedures cover hazardous shipments like lithium-ion batteries, explosives, flammable liquids, and compressed gases that lack required warning labels or shipping documents.

---

This article originally appeared on CultureMap.com.

Texas A&M, UH rise in global rankings of universities attracting the most attention

visibility report

Houston and Texas universities had a strong showing on the 2026-27 Global University Visibility (GUV) Rankings compiled by D.C.-based higher ed market research firm American Caldwell.

Texas A&M ranked No. 6 on the list—the top rank of any Texas university. Meanwhile, the University of Houston ranked No. 52, a 15-spot jump from its previous ranking.

The GUV rankings rate colleges that garner the most global attention via news coverage, social media influence, website traffic, YouTube views, and general public interest. GUV evaluated over 1,200 universities across 193 United Nations-recognized countries.

Texas A&M, with its No. 6 global ranking, also claimed the No. 5 spot among U.S. institutions. The university climbed 21 spots from its previous rank.

“News mentions were a driver of Texas A&M’s movement in this year’s rankings, and earned media remains one of the strongest signals of relevance,” Tim Doty, associate vice president for earned media at Texas A&M, said in a news release. “Much of that visibility begins with our faculty and research experts, whose work helps explain, solve and give context to issues people care about. When Texas A&M experts appear in news stories about research, discovery, national security, agriculture, health, engineering, service and the future of Texas, audiences see the university not only as large or well known, but as useful, relevant and necessary to the conversations shaping our state and country.”

In the “Public Interest” category, UH also claimed a top 10 global ranking at No.6. UH touts its overall GUV rankings success to Guggenheim Fellowships, MacArthur “Genius” grants, National Academy membership, studies like researchers breaking the superconductivity temperature record, and success on the football field and basketball courts.

“Across the board, there is no question that the University of Houston is a brand on the rise,” Shawn Lindsey, interim vice president for marketing and communications, said in a news release. “People are seeing our story, hearing about the amazing things happening at UH and actively seeking us out to learn more. We are seeing it in record-high student applications, we are seeing increases in trademark licensing revenue, our faculty are earning global accolades. It’s an exciting time to be a Houston Cougar.”

Other Texas institutions to make the top 250 on the list include:

  • No. 22 The University of Texas at Austin
  • No. 104 University of Texas at Dallas
  • No. 159 Texas Tech University
  • No. 178 Rice University
  • No. 191 University of North Texas
  • No. 248 Texas State University

For the fourth year in a row, Harvard University secured the top spot on the list, followed by MIT, Stanford University and Purdue University. The University of Oxford was the top non-U.S. institution at No. 5.

See the full list here.

View All Listings